AZILSIGN-CT TAB - Dr Precision

1. Product Overview

AZILSIGN-CT Tablet is a combination antihypertensive medication that integrates two powerful agents: Azilsartan Medoxomil (an ARB) and Chlorthalidone (a thiazide-like diuretic).

It is designed for once-daily oral administration and is especially suitable for patients who require dual therapy for effective blood pressure control.

The combination provides synergistic effects—Azilsartan relaxes vascular smooth muscle, and Chlorthalidone decreases plasma volume—leading to optimal antihypertensive outcomes.

2. Composition and Strengths

Active Ingredients:

Azilsartan Medoxomil: Typically 40 mg or 80 mg

Chlorthalidone: Typically 12.5 mg or 25 mg

Formulated in film-coated tablet form to enhance patient compliance and stability.

Available in various strengths to suit titration needs and patient-specific therapy.

3. Mechanism of Action

Azilsartan Medoxomil:

A selective angiotensin II receptor type 1 (AT1) blocker, it prevents angiotensin II from binding to AT1 receptors.

Results in vasodilation, reduced aldosterone secretion, and lower blood pressure.

Has high affinity for the AT1 receptor and offers sustained 24-hour blood pressure control.

Chlorthalidone:

A long-acting diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule of the nephron.

Leads to increased excretion of sodium, chloride, and water, thereby reducing plasma volume.

Also has mild vasodilatory effects and contributes to long-term cardiovascular protection.

4. Therapeutic Uses

Indicated for the treatment of essential hypertension in adults.

Used in patients who do not achieve adequate control with monotherapy.

May reduce the risk of stroke, myocardial infarction, heart failure, and kidney complications.

Especially beneficial in patients with salt sensitivity, fluid overload, or coexisting diabetes mellitus.

5. Clinical Benefits

Provides superior 24-hour blood pressure reduction compared to ARBs alone.

Helps in managing resistant hypertension where monotherapy is ineffective.

Reduces morning surge in blood pressure, which is associated with higher cardiovascular risk.

Improves patient adherence by offering two medications in a single, once-daily tablet.

Lower incidence of edema compared to calcium channel blockers.